Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy Urban adolescents in the United States

Pediatric Infectious Disease Journal

Volumn 29, Issue 6, 2010, Pages 530-534

  Cunningham, Coleen K ^a   Rudy, Bret J ^b   Xu, Jiahong ^c   Bethel, James ^c   Kapogiannis, Bill G ^d   Ahmad, Sushma ^c   Wilson, Craig M ^e   Flynn, Patricia M ^f  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c WESTAT   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adolescents; Hepatitis B; Immunogenicity; Vaccination

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT VACCINE; VACCINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNICITY; FEMALE; HEPATITIS B; HETEROSEXUALITY; HISPANIC; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; UNITED STATES; UNSPECIFIED SIDE EFFECT; URBAN POPULATION; VACCINATION; BLOOD; IMMUNIZATION; IMMUNOLOGY; MULTICENTER STUDY;

ADOLESCENT; CHILD; FEMALE; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; SINGLE-BLIND METHOD; UNITED STATES; URBAN POPULATION; VACCINES, COMBINED; VACCINES, SYNTHETIC;

EID: 77953166602     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181d285c7     Document Type: Article

References (22)

1. Update: recommendations to prevent hepatitis B virus transmission-United States. MMWR Morb Mortal Wkly Rep. 1995;44:574-575.
2. Anonymous. Update: recommendations to prevent hepatitis B virus transmission - United States. MMWR Morb Mortal Wkly Rep. 1999;48:33-34.
3. Wong VK, Woodruff C, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Pediatr Infect Dis J. 1994;13:936.
4. Middleman AB, Robertson LM, Young C, et al. Predictors of time to completion of hepatitis B vaccination series among adolescents. J Adolesc Health. 1999;25:323-327.
5. Laneman H, Pastore DR, Steed N, et al. Adolescent hepatitis B vaccination: comparison among two high school-based health centers and an adolescent clinic. Arch Pediatr Adolesc Med. 2000;154:1085-1088.
6. Van der Wielin M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and B vaccination in children ages one to eleven years. Pediatr Infect Dis J. 2000;19:848-853.
7. Cassidy WM, Watson B, Ioli VA, et al. A randomized trial with alternative two- and three- dose hepatitis B vaccination regimes in adolescents: antibody responses, safety, and immunologic memory. Pediatrics. 2001; 107:626-631.
8. Schiff GM, Sherwood JR, Zeldis JB, et al. Comparative study of immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health. 1995;16:12-17.
9. Wilson CM, Ellenberg JH, Sawyer MK, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. J Adolesc Health. 2001;29S:123-129.
10. Burgess MA, Rodger AJ, Waite SA, et al. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomized study. Vaccine. 2001;19:4835-4841.
11. Knöll A, Hottenträger B, Kainz J, et al. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine. 2000;18:2029-2032.
12. Anonymous. Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11-15 years. MMWR Morb Mortal Wkly Rep. 2000;49:261.
13. Van Herck K, Van Damme P, Collard F, et al. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years. Scand J Gastroenterology. 1999;34:1236-1240.
14. Miñana JS, Ganuga MG, Millán PF, et al. Hepatitis B vaccine immunono-responsiveness in adolescents: a revaccination proposal after primary vaccination. Vaccine. 1996;14:103-106.
15. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999;103:1243-1247.
16. Horowitz MM, Ershler WB, McKinney WP, et al. Duration of immunity after hepatitis B vaccination: efficacy of low dose booster vaccine. Ann Intern Med. 1988;108:185-189.
17. Wenter AP, Follett EA, McIntyre J, et al. Influence of smoking on immunological response to hepatitis B vaccine. Vaccine. 1994;12:771-772.
18. Anonymous. Reduced development of anti-HBS in vaccinated health care workers. Infect Dis Alert. 1993;79-80.
19. Bock HL, Kruppenbacher J, Sanger R, et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med. 1996;156:2226-2231.
20. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men: N Engl J Med. 1986;315:209-214.
21. Odaka N, Eldred L, Cohn S, et al. Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccine in homosexual men. JAMA. 1998;260:3635-3637.
22. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol. 1988;6:201-207.